70 related articles for article (PubMed ID: 21933787)
1. Suitability of a new antimicrobial aminosterol formulation for aerosol delivery in cystic fibrosis.
Alhanout K; Brunel JM; Dubus JC; Rolain JM; Andrieu V
J Antimicrob Chemother; 2011 Dec; 66(12):2797-800. PubMed ID: 21933787
[TBL] [Abstract][Full Text] [Related]
2. In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis.
Alhanout K; Brunel JM; Raoult D; Rolain JM
J Antimicrob Chemother; 2009 Oct; 64(4):810-4. PubMed ID: 19666647
[TBL] [Abstract][Full Text] [Related]
3. Basis for nebulized antibiotics: droplet characterization and in vitro antimicrobial activity versus Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
Todisco T; Eslami A; Baglioni S; Sposini T; Tascini C; Sommer E; Knoch M
J Aerosol Med; 2000; 13(1):11-6. PubMed ID: 10947319
[TBL] [Abstract][Full Text] [Related]
4. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.
King P; Citron DM; Griffith DC; Lomovskaya O; Dudley MN
Diagn Microbiol Infect Dis; 2010 Feb; 66(2):181-6. PubMed ID: 19828274
[TBL] [Abstract][Full Text] [Related]
5. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin.
Halwani M; Blomme S; Suntres ZE; Alipour M; Azghani AO; Kumar A; Omri A
Int J Pharm; 2008 Jun; 358(1-2):278-84. PubMed ID: 18448284
[TBL] [Abstract][Full Text] [Related]
6. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment.
MacLeod DL; Nelson LE; Shawar RM; Lin BB; Lockwood LG; Dirk JE; Miller GH; Burns JL; Garber RL
J Infect Dis; 2000 Mar; 181(3):1180-4. PubMed ID: 10720551
[TBL] [Abstract][Full Text] [Related]
7. Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients.
Rottier BL; van Erp CJ; Sluyter TS; Heijerman HG; Frijlink HW; Boer AH
J Aerosol Med Pulm Drug Deliv; 2009 Sep; 22(3):263-9. PubMed ID: 19466906
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM
J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
[TBL] [Abstract][Full Text] [Related]
9. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
10. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients.
Hogardt M; Schmoldt S; Götzfried M; Adler K; Heesemann J
J Antimicrob Chemother; 2004 Dec; 54(6):1057-61. PubMed ID: 15509615
[TBL] [Abstract][Full Text] [Related]
11. Soluble squalamine tablets for the rapid disinfection of home nebulizers of cystic fibrosis patients.
Djouhri-Bouktab L; Alhanout K; Andrieu V; Stremler N; Dubus JC; Raoult D; Rolain JM; Brunel JM
J Cyst Fibros; 2012 Dec; 11(6):555-9. PubMed ID: 22727722
[TBL] [Abstract][Full Text] [Related]
12. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
Assael BM
Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
[TBL] [Abstract][Full Text] [Related]
13. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
Adi H; Young PM; Chan HK; Agus H; Traini D
Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286
[TBL] [Abstract][Full Text] [Related]
14. Stability and antibacterial potency of ceftazidime and vancomycin eyedrops reconstituted in BSS against Pseudomonas aeruginosa and Staphylococcus aureus.
Karampatakis V; Papanikolaou T; Giannousis M; Goulas A; Mandraveli K; Kilmpasani M; Alexiou-Daniel S; Mirtsou-Fidani V
Acta Ophthalmol; 2009 Aug; 87(5):555-8. PubMed ID: 18700884
[TBL] [Abstract][Full Text] [Related]
15. Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer.
Le Brun PP; de Boer AH; Gjaltema D; Hagedoorn P; Heijerman HG; Frijlink HW
Int J Pharm; 1999 Nov; 189(2):205-14. PubMed ID: 10536249
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antibacterial activity of novel enolphosphate derivatives.
Grison C; Barthes N; Finance C; Duval RE
Bioorg Chem; 2010 Oct; 38(5):218-23. PubMed ID: 20655569
[TBL] [Abstract][Full Text] [Related]
17. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model.
Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ
Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647
[TBL] [Abstract][Full Text] [Related]
18. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
Ratjen F; Brockhaus F; Angyalosi G
J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
[TBL] [Abstract][Full Text] [Related]
19. Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation.
Prescrire Int; 2002 Dec; 11(62):177-8. PubMed ID: 12469696
[TBL] [Abstract][Full Text] [Related]
20. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
